University of Kent biotechnology available for commercial use could cut costs of producing proteins for everything from diagnostics to cancer therapeutics. A recent collaboration between Kent scientists and the Science and Technology Facilities Council-supported Central Laser Facility (CLF), has affirmed the remarkable versatility of the technology in expanding the possibilities of protein production. The Vesicle Nucleating Peptide (VNp) technology, which underpins Kent spin-out company, Sirius Proteins, dramatically increases the yield, simplicity and scope of recombinant protein production in bacteria. This makes it easier and more affordable to produce more complex…
Read MoreSpin-out technology promises to cut costs of protein production
